<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769274</url>
  </required_header>
  <id_info>
    <org_study_id>B3291006</org_study_id>
    <nct_id>NCT01769274</nct_id>
  </id_info>
  <brief_title>Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia</brief_title>
  <acronym>IEM</acronym>
  <official_title>A Randomized, Double Blind Third Party Open Placebo-Controlled Exploratory Study To Evaluate The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of single doses of
      PF-05089771 against placebo in treatment of pain in patients with primary, inherited
      erythromelalgia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average pain score postdose based on Pain Intensity Numerical Rating Scale (PI-NRS) scores</measure>
    <time_frame>0-4 hr postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum pain score postdose based on Pain Intensity Numerical Rating Scale scores.</measure>
    <time_frame>0-4 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of time above Pain Intensity Numerical Rating Scale score of 5.</measure>
    <time_frame>0-4hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average pain score post Evoked Pain (EP) timepoint 2 based on Pain Intensity Numerical Rating Scale scores.</measure>
    <time_frame>4-8 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum pain score post Evoked Pain timepoint 2 based on maximum Pain Intensity Numerical Rating Scale scores.</measure>
    <time_frame>4-8h hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of time above Pain Intensity Numerical Rating Scale score of 5 in the period post Evoked Pain timepoint 2</measure>
    <time_frame>4-8 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average pain score post Evoked Pain timepoint 3 based on Pain Intensity Numerical Rating scale scores</measure>
    <time_frame>8-10 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum pain score post Evoked Pain timepoint 3 based on maximum Pain Intensity Numerical Rating Scale scores</measure>
    <time_frame>8-10 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of time above Pain Intensity Numerical Rating Scale score of 5 post Evoked Pain timepoint 3</measure>
    <time_frame>8-10 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average pain score post Evoked Pain timepoint 4 based on Pain Intensity Numerical Rating scale scores</measure>
    <time_frame>24-28 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum pain score post Evoked Pain timepoint 4 based on maximum Pain Intensity Numerical Rating Scale scores</measure>
    <time_frame>24-28 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of time above Pain Intensity Numerical Rating Scale score of 5 post Evoked Pain timepoint 4</measure>
    <time_frame>24-28 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global satisfaction with study medication based on categorical rating scale</measure>
    <time_frame>4 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue therapy or medication post dose</measure>
    <time_frame>0-28 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PF-05089771, maximum observed concentration (Cmax), time to maximum concentration (Tmax)</measure>
    <time_frame>Day 1 predose, then 0.5hr, 2hr, 4hr, 6hr and 24hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, incidence and severity of Laboratory test result abnormalities as a measure of safety and toleration</measure>
    <time_frame>Day 0, Day 2; 24 hr postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, incidence and severity of Adverse Events in study subjects</measure>
    <time_frame>up to 28 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure changes of clinical significance, as a measure of safety and toleration</measure>
    <time_frame>Day -2, Day -1, Predose and 6hr post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram changes of clinical significance, as a measure of safety and toleration</measure>
    <time_frame>Day -2, predose, 6 hr 24 hr post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate changes of clinical significance, as a measure of safety and toleration</measure>
    <time_frame>Day -2, Day -1, Predose and 6hr post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for first rescue therapy or medication postdose</measure>
    <time_frame>0-28 hr postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Inherited Erythromelalgia</condition>
  <arm_group>
    <arm_group_label>PF-05089771 1600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator: matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo for PF-05089771 1600 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.</description>
    <arm_group_label>PF-05089771 1600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.</description>
    <arm_group_label>Placebo comparator: matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and or female subjects between the ages of 18-78 years

          -  Subject has clinical signs of IEM

          -  Minimum BMI 17.5kg/m2 and total body weight &gt;50kg

        Exclusion Criteria:

          -  Other severe pain conditions, e.g. rheumatologic, that may impair subject's
             self-assessment of pain due to IEM.

          -  Evidence of clinically significant hypertension, clinically significant hematological,
             dermatological, renal, endocrine (except diabetes mellitus), pulmonary,
             gastrointestinal, cardiovascular, hepatic, neurological (other than IEM), or allergic
             disease (including drug allergies but excluding untreated asymptomatic seasonal
             allergies).

          -  Subjects with severe obesity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291006&amp;StudyName=%20Evaluation%20Of%20The%20Efficacy%20And%20Safety%20Of%20Single%20Doses%20Of%20PF-05089771%20In%20Patients%20With%20Primary%20%28Inherited%29%20Erythromelalgia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <disposition_first_submitted>July 30, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 30, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 6, 2013</disposition_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromelalgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

